Klaria Interim Report Q1 2021
Klaria Interim Report Q1 2021Summary of the Interim Report Option agreement for the US rights to Epinephrine Alginate Film signed with Imbrium Therapeutics FIRST QUARTER 2021 · Net sales amounted to 0.0 MSEK (0.0 MSEK) · Other income amounted to 31.3 MSEK (1.5 MSEK) · R&D costs for the period amounted to 11.4 MSEK (8.0 MSEK) · Profit after tax amounted to 16.7 MSEK (-11.0 MSEK) · Earnings per share for the quarter amounted to 0.32 SEK (-0.32 SEK) · Cash flow from operating activities amounted to 17.1 MSEK (0.4 MSEK) · Cash and cash equivalents on the balance day